Literature DB >> 10997

Interactions between phospholipids and barbiturates.

A G Lee.   

Abstract

The effects of a number of barbiturates on the temperature of the lipid phase transition have been studied using chlorophyll a as a fluorescence probe. The barbiturates cause a reduction in the temperature of the phase transitions of dipalmitoyl phosphatidylcholine and dipalmitoyl phosphatidylethanolamine, the effects being greatest at lower pH values where more of the barbiturate is present in the uncharged form. There was no significant interaction between the barbiturates and dipalmitoyl phosphatidylserine. These and other observations on the actions of local anaesthetics are used to develop a model for local anaesthesia. It is suggested that the sodium channel is surrounded by an annulus of lipid in the gel state, this rigid microenvironment preventing the sodium channel relaxing from its active configuration to an inactive one. Local anaesthetics, which reduce the temperature of lipid phase transitions, trigger a change of the annular lipid from the gel to the liquid-crystalline state, with a consequent relaxation of the sodium channel to an inactive configuration, in which the sodium current is reduced or blocked.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10997     DOI: 10.1016/0005-2736(76)90156-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  d-Amphetamine binding to brain lipid.

Authors:  M A Goldberg; T Todoroff
Journal:  Neurochem Res       Date:  1978-12       Impact factor: 3.996

2.  Glucagon-stimulated adenylate cyclase detects a selective perturbation of the inner half of the liver plasma-membrane bilayer achieved by the local anaesthetic prilocaine.

Authors:  M D Houslay; I Dipple; S Rawal; R D Sauerheber; J A Esgate; L M Gordon
Journal:  Biochem J       Date:  1980-07-15       Impact factor: 3.857

3.  Anesthetics may restructure the hydrogen belts of membranes.

Authors:  H Brockerhoff
Journal:  Lipids       Date:  1982-12       Impact factor: 1.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.